Human Health Holdings Ltd

Human Health Holdings Ltd has an equal number of basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities at present. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

The company's profitability metrics, such as return on invested capital (ROIC) and operating margins, are not available in the valuation snapshot, making it difficult to assess its performance relative to industry benchmarks. Without these metrics, a direct comparison to the cohort medians and preferred industry metrics cannot be made.

Segment and geographic exposure details are not disclosed in the available data, which limits the ability to evaluate revenue concentration or geographic diversification. This lack of information also hinders the assessment of potential risks associated with over-reliance on specific markets or product lines.

The company's growth trajectory is constrained by the absence of detailed revenue history and outlook data. Analyst estimates indicate a last actual revenue of 480,258,000 HKD and an EPS of 0.09 HKD, but no forward-looking guidance is provided to assess future performance.

Risk factors include the unassessed liquidity risk and the potential for dilution, although the current dilution risk is categorized as low. The absence of detailed risk assessments and the lack of going-concern language in the source documents suggest a need for further scrutiny of the company's financial health.

Recent events, such as filings and transcripts, are not detailed in the available data, which limits the ability to understand the company's recent strategic moves or operational changes.

Revenue HK$644.4M, +9,1% YoY; Operating income +1,9% YoY.

• ▍Revenue HK$644.4M, +9,1% YoY
• ▍Operating income +1,9% YoY
• ▍Net income +8,9% YoY
• ▍Free cash flow +1 887,2% YoY
• ▍Net margin 4.1%